For instance, patients with metabolic HFpEF might benefit more from SGLT2 inhibitors, GLP-1 receptor agonists, or structured weight loss programs, while patients who are AF-dominant might derive disproportionate benefit from rhythm control strategies or anticoagulation intensification [65]. This evidence concerns the gene GLP1R and atrial fibrillation.